# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001171843-19-001171
Filing Date
2019-02-25
Accepted
2019-02-25 09:17:38
Documents
4
Period of Report
2019-02-23
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | FORM 8-K | f8k_022519.htm | 8-K | 15987
2 | PRESS RELEASE | exh_991.htm | EX-99.1 | 9771
3 | EXHIBIT 99.2 | exh_992.htm | EX-99.2 | 602
4 |  | poster.jpg | GRAPHIC | 1691933
| Complete submission text file | 0001171843-19-001171.txt |  | 2357622

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 19628220
SIC: 2836 Biological Products, (No Diagnostic Substances)